Table 6.
Subgroup analysis of patients with positive TSH receptor antibody.
| Result | Benign (N = 84) | PTC (N = 9) | p value |
|---|---|---|---|
| Gender, female (%) | 59 (70.2) | 9 (100) | 0.057 |
| Age (years) | 36.7 ± 12.5 | 48.9 ± 9.6 | 0.006 |
| BMI (kg/m2) | 23.6 ± 4.3 | 24.0 ± 5.5 | 0.793 |
| TSH (mIU/L) | 0.9 ± 4.9 | 1.1 ± 1.3 | 0.915 |
| TSH with group | 0.018 | ||
| (i) Group 1 (<0.14) | 67 (81.7) | 3 (37.5) | |
| (ii) Group 2 (0.14–1.04) | 4 (4.9) | 1 (12.5) | |
| (iii) Group 3 (1.04–1.92) | 3 (3.7) | 2 (25) | |
| (iv) Group 4 (>1.92) | 8 (9.8) | 2 (25) | |
| FT4 (ng/dl) | 2.7 ± 2.1 | 1.7 ± 1.2 | 0.206 |
| T4 (μg/dl) | 9.7 ± 5.0 | 10.7 ± 4.9 | 0.707 |
| T3 (ng/dl) | 194.9 ± 96.4 | 167.5 ± 50.6 | 0.578 |
| Anti-TPO Ab positive (%) | 41 (77.4) | 3 (42.9) | 0.052 |
| Anti-Tg Ab positive (%) | 6 (46.2) | 1 (33.3) | 0.687 |
| MicroPTC (%) | 5 (55.6) | ||
| Stage | 1 | 9 (100) | |
| 2 | 0 (0) | ||
| 3 | 0 (0) | ||
| 4 | 0 (0) | ||
| LN metastasis (%) | 1 (11.1) | ||
| Synchronous nonthyroidal malignancies or tumors (%) | 1 (11.1) |
PTC: papillary thyroid cancer; BMI: body mass index; TSH: thyroid-stimulating hormone; FT4: free thyroxine; T4: thyroxine; T3: triiodothyronine; anti-TPO Ab: thyroid peroxidase antibodies; anti-TG Ab: antithyroglobulin antibody; HT: Hashimoto's thyroiditis; microPTC: papillary thyroid microcarcinoma; LN: lymph node.